Boehringer Ingelheim is one of the world's largest privately-held pharmaceutical companies, developing human pharmaceuticals (respiratory, cardiometabolic, oncology, immunology, mental health, retinal health), animal health, and biopharmaceutical contract manufacturing. Its respiratory portfolio includes Spiriva, Spiriva Respimat, OFEV (nintedanib) for IPF, and the newly EU-approved Jascayd (nerandomilast).
UK first in Europe to clear Boehringer's IPF drug Jascayd Boehringer Ingelheim has the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, after the UK's MHRA gave a green light to the drug. Phosphodiesterase (PDE) 4B inhibitor Jascayd (nerandomilast) has been cleared as a twice-daily, oral therapy for adults with IPF as well as progressive pulmonary fibrosis (PPF), an umbrella term for diseases caused by progressive scarring to the lungs.